| Journal: | Revista médica del Instituto Mexicano del Seguro Social |
| Database: | PERIÓDICA |
| System number: | 000417473 |
| ISSN: | 0443-5117 |
| Authors: | García Alvarez, José Luis1 Sánchez Tovar, Marisol2 García Vigil, José Luis3 |
| Institutions: | 1Instituto Mexicano del Seguro Social, Hospital General de Zona 24, México, Distrito Federal. México 2Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar 42, México, Distrito Federal. México 3Comisión Interinstitucional del Cuadro Básico de Insumos del Sector Salud, México, Distrito Federal. México |
| Year: | 2009 |
| Season: | Ene-Feb |
| Volumen: | 47 |
| Number: | 1 |
| Pages: | 7-16 |
| Country: | México |
| Language: | Español |
| Document type: | Revisión bibliográfica |
| Approach: | Analítico |
| Spanish abstract | Objetivo: evaluar el uso de antioxidantes, antiagregantes plaquetarios, estatinas y moduladores de la inflamación en la reducción del riesgo cardiovascular. Métodos: se realizó una búsqueda de ensayos clínicos en los que se investigó el uso de antioxidantes, antiagregantes plaquetarios, estatinas y moduladores de la inflamación para la prevención primaria y secundaria de riesgo cardiovascular. Se analizaron con revisión sistemática, aplicando metaanálisis para la combinación de resultados. Resultados: se incluyeron 20 estudios. En el subgrupo de vitamina E se presentaron 3623 eventos de IAM no fatal, RR = 1 (0.93-1.06) IC 95 %, p = 0.01. En estatinas se presentaron 2795 eventos de IAM no fatal, RR = 0.68 (0.63-0.73) IC 95 %, p = 0.02. En antiagregantes plaquetarios se presentaron 1199 eventos de IAM no fatal, RR = 0.91 (0.81- 1.02) IC 95 %, p = 0.42. En ácidos grasos omega-3 se presentaron 434 eventos de IAM no fatal, RR = 0.93 (0.76-1.13) IC 95 %, p = 0.002. Conclusiones: la vitamina E no reduce el riesgo cardiovascular, en comparación con la estatinas, antiagregantes plaquetarios y ácidos grasos omega-3 |
| English abstract | Objective: to evaluate if used of medication with antioxidants, antiplatelets, statins and modulators of inflammation reduces effectively the risk of presenting a cardiovascular disease (CVD). Methods: a search on clinical trials (randomized, double blind and controlled clinical studies) in which the use of antioxidants, antiplatelets, statins and modulators of inflammation were investigated for the primary and secondary prevention of CVD. The selected studies were analyzed by a systematic revision, applying the meta-analysis. Results: 20 studies were included. In the subgroup of vitamin E 3623 events of the non fatal acute myocardial infarction (AMI) appeared, RR = 1 (0.93-1.06) IC 95 %, p = 0.01. In the subgroup of statins 2795 events of non fatal acute myocardial infarction (AMI) appeared, RR = 0.68 (0.63-0.73) IC 95 %, p = 0.02. In the subgroup of antiplatelets 1199 events of non fatal AMI appeared, RR = 0. 91 (0.81-1.02) IC 95 %, p = 0.42. In the subgroup of ω-3 fatty acids 434 events of the non fatal AMI appeared, RR = 0.93 (0.76-1.13) IC 95 %, p = 0.002. Conclusions: vitamin E did not show any benefit, in comparison with the antiplatelets, statins, and ω-3 fatty acids |
| Disciplines: | Medicina |
| Keyword: | Sistema cardiovascular, Farmacología, Antioxidantes, Estrés oxidativo, Riesgo cardiovascular |
| Keyword: | Cardiovascular system, Pharmacology, Antioxidants, Oxidative stress, Cardiovascular risk |
| Full text: | Texto completo (Ver PDF) |
